Gilead Sciences

Gilead Sciences (Nasdaq/NYSE: GILD) is a Biotechnology company operating within the Health Care sector of the US equity market.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

The company reports trailing twelve-month revenue of $7.42B and net income of $2.02B.

Key metrics include a return on equity of 8.6%.

Use FINOTAUR to track GILD's price action, review fundamentals, and stay current with company news — all in one research dashboard.